This Phase 1 study is designed to characterize the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of IMGN151 in patients with recurrent endometrial cancer, or recurrent, high-grade serous epithelial ovarian cancer, primary peritoneal, or fallopian tube cancers. All patients will be, in the opinion of the investigator, appropriate for nonplatinum single-agent therapy for their next line of therapy.
IMGN151-1001 is a Phase 1, first in human, open-label dose-escalation and expansion study in adult patients with recurrent endometrial cancer, recurrent, high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancers.